

SCIENTIFIC ADVISORY COMMITTEE ON ALTERNATIVE TOXICOLOGICAL METHODS (SACATM)
Preliminary Agenda

Hilton Arlington
950 North Stafford Street, Arlington, VA 22203
June 16 – 17, 2011

JUNE 16

8:30 AM	Introductions	Dr. Steven Niemi, Massachusetts General Hospital, SACATM Chair
8:40	Welcome and Opening Remarks	Dr. Linda Birnbaum, NIEHS/NTP Dr. John Bucher, NIEHS/NTP Dr. Jodie Kulpa-Eddy, USDA, ICCVAM Chair
9:10	Welcome and NICEATM-ICCVAM Update	Dr. William Stokes, NIEHS/NTP
	<ul style="list-style-type: none">• NICEATM-ICCVAM Activities• Regulatory Acceptance and Availability of ICCVAM-Recommended Alternative Test Methods• Public Comments• SACATM Discussion	Dr. Niemi
10:00	BREAK	
10:30	Report on Peer Review Panel Meeting: Evaluation of an <i>In Vitro</i> Estrogen Receptor Transcriptional Activation Test Method for Endocrine Disruptor Chemical Screening	
	<ul style="list-style-type: none">• Introduction and Overview of Proposed Methods and Applications• Overview of Panel Report• Public Comments• SACATM Discussion	Dr. Warren Casey, NIEHS/NTP Dr. John Vandenberg, Panel Chair, NC State Dr. Niemi
12:00 PM	LUNCH	
1:00	Federal Agency Research, Development, Translation, and Validation Activities Relevant to the NICEATM-ICCVAM Five-Year Plan: NIH Update	
	<ul style="list-style-type: none">• Introduction• NIH Research Progress and Priorities• SBIR Grants and Contracts• Public Comments• SACATM Discussion	Dr. Margaret Snyder, NIH Dr. Francis Collins, NIH (or designee) Dr. Daniel Shaughnessy, NIEHS Dr. Niemi
2:30	BREAK	
3:00	Nominations to ICCVAM (ACTION)	
	<ul style="list-style-type: none">• Introduction• Botulinum <i>In Vitro</i> Assays• <i>In Vitro</i> Pyrogen Assay Validation• Public Comments• SACATM Discussion and Vote	Dr. Kulpa-Eddy Dr. F. Naomi Zeytin, Biosentinel Inc. Dr. Thomas Hartung, Biotest AG Dr. Niemi
4:30	Report from the ICCVAM Workshop Series on Best Practices for Regulatory Safety Testing	
	<ul style="list-style-type: none">• Assessing the Potential for Chemically Induced Eye Injuries• Assessing the Potential for Chemically Induced Allergic Contact Dermatitis• Public Comments• SACATM Discussion	Dr. Jill Merrill, FDA Dr. Joanna Matheson, CPSC, ICCVAM Vice-chair Drs. Eugene Elmore, University of California - Irvine and Michael Olson, GlaxoSmithKline Dr. Niemi
5:30	ADJOURN	

JUNE 17

8:30 AM	Introductions	Dr. Niemi
8:40	Report and Recommendations from the International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in Vaccine Potency Testing: State of the Science and Future Directions <ul style="list-style-type: none">• Public Comments• SACATM Discussion	Dr. Kulpa-Eddy Dr. Richard McFarland, FDA
10:00	BREAK	Dr. Niemi
10:30	Updates on International Collaborations <ul style="list-style-type: none">• Korean Center for the Validation of Alternative Methods• Health Canada• Japanese Center for the Validation of Alternative Methods• European Centre for the Validation of Alternative Methods	Dr. Soojung Sohn, KoCVAM Mr. Michael Inskip, Health Canada Dr. Hajime Kojima, JaCVAM TBD, ECVAM
12:00 PM	Other Business	Dr. Niemi
12:15	ADJOURN	Dr. Niemi

Preliminary Draft May 7, 2011